Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Feb 20, 2026

In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)
06:48

In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)

Published on: August 1, 2025

578

Anaplastic large-cell lymphoma.

Giorgio Inghirami1, Stefano A Pileri,

  • 1Department of Pathology and Center for Experimental Research and Medical Studies, University of Torino, Turin, Italy. giorgio.inghirami@unito.it

Seminars in Diagnostic Pathology
|August 20, 2011
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spatial remodeling of bone marrow architecture defines tissue-state signatures of disease activity and therapeutic response in myelodysplastic neoplasms.

Leukemia·2026
Same author

A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma.

Blood cancer discovery·2026
Same author

Pathogenesis of diffuse large B cell lymphoma proteogenotypes.

Cancer cell·2026
Same author

Can we target CTCL clonal evolution and improve outcomes?

Blood·2026
Same author

Tet2 deficiency alters CD4+ T cell function and promotes T cell lymphoma with a TFH cell immunophenotype.

The Journal of experimental medicine·2026
Same author

MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma.

Blood advances·2026
Same journal

Update on the molecular pathology of the distinctive giant cell, fibro-osseous and bone forming lesions of the jaws.

Seminars in diagnostic pathology·2026
Same journal

Update on the molecular pathology and classification of odontogenic cysts and tumours.

Seminars in diagnostic pathology·2026
Same journal

MDM2 gene amplification in surgical pathology: biology, diagnostic utility, and clinical relevance in the modern era.

Seminars in diagnostic pathology·2026
Same journal

When three negatives equal a positive: Molecular updates of triple-negative breast carcinomas with favorable prognoses.

Seminars in diagnostic pathology·2026
Same journal

Old school, new insight: Revisiting histomorphology in the modern era of prostate cancer risk stratification.

Seminars in diagnostic pathology·2026
Same journal

Recent advances in genetic predisposition to primary testicular tumors.

Seminars in diagnostic pathology·2026
See all related articles

Anaplastic large-cell lymphoma (ALCL) understanding has evolved, leading to updated classifications. This review details ALCL

Area of Science:

  • Hematology
  • Oncology
  • Pathology

Background:

  • Anaplastic large-cell lymphoma (ALCL) classification has undergone significant evolution.
  • New insights into cell of origin, biology, genetics, and clinical presentation have refined understanding.

Purpose of the Study:

  • To present updated cytologic and histologic features of ALCL.
  • To highlight diagnostic algorithms and genetic aberrations.
  • To briefly illustrate clinical features and tailored treatment strategies.

Main Methods:

  • Review of current literature and World Health Organization classifications.
  • Analysis of cytologic and histologic findings.
  • Description of genetic aberrations and pathogenetic mechanisms.

More Related Videos

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.9K
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.6K

Related Experiment Videos

Last Updated: Feb 20, 2026

In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)
06:48

In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)

Published on: August 1, 2025

578
Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.9K
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.6K

Main Results:

  • The World Health Organization classification reflects recent advancements in ALCL understanding.
  • Detailed diagnostic criteria and genetic profiles are presented.
  • Clinical manifestations and therapeutic approaches are summarized.

Conclusions:

  • Updated knowledge has led to a revised classification of ALCL.
  • Comprehensive understanding of ALCL requires integrating cytologic, histologic, genetic, and clinical data.
  • Future strategies will focus on tailored therapeutic approaches based on novel insights.